We are live on ! Find out more
CVAC

CureVac

Delisted

CVAC was delisted on the 5th of January, 2026.

112 hedge funds and large institutions have $750M invested in CureVac in 2021 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 36 increasing their positions, 30 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 30

14% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 28

3% more funds holding

Funds holding: 109112 (+3)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.08% less ownership

Funds ownership: 7.43%7.35% (-0.08%)

26% less capital invested

Capital invested by funds: $1.02B → $750M (-$269M)

46% less call options, than puts

Call options by funds: $70M | Put options by funds: $129M

Holders
112
Holders Change
+3
Holders Change %
+2.75%
% of All Funds
0%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0%
New
32
Increased
36
Reduced
30
Closed
28
Calls
$70M
Puts
$129M
Net Calls
-$59.2M
Net Calls Change
-$75.2M

CVAC Hedge Fund Activity: Q3 2021 in Review

112 institutional investors reported a position in CureVac (CVAC) for Q3 2021, worth a combined $750M — down 26% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new CVAC positions and 28 closed out — a net gain of 4 holders — while 36 added to existing stakes and 30 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $28.9M. The largest seller was Baillie Gifford & Co, cutting an estimated $94.9M.

  • 112 institutional investors held CureVac (CVAC) as of Q3 2021, up from 109 in Q2 2021.
  • Funds reported $750M of CureVac stock for Q3 2021, down 26% quarter-over-quarter.
  • 32 funds opened new CureVac positions in Q3 2021 and 28 closed out, a net change of +4 holders.
  • The largest CureVac buyer in Q3 2021 was T. Rowe Price Associates, an estimated $28.9M added.
  • The largest CureVac seller in Q3 2021 was Baillie Gifford & Co, an estimated $94.9M sold.

Based on aggregated 13F filings for Q3 2021.